Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer

被引：3
|
作者：
Hudis, CA [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY 10021 USA
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2006年 / 3卷 / 01期
关键词：
breast cancer; chemotherapy; HER2; survival; trastuzumab;
D O I：
10.1038/ncponc0401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 13
页数：2
相关论文
共 50 条
  • [41] Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab
    Jacquinot, Quentin
    Meneveau, Nathalie
    Falcoz, Antoine
    Bouhaddi, Malika
    Roux, Pauline
    Degano, Bruno
    Chatot, Marion
    Curtit, Elsa
    Mansi, Laura
    Paillard, Marie-Justine
    Bazan, Fernando
    Chaigneau, Loic
    Dobi, Erion
    Meynard, Guillaume
    Vernerey, Dewi
    Pivot, Xavier
    Mougin, Fabienne
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [42] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Kurebayashi, Junichi
    Kanomata, Naoki
    Yamashita, Tetsumasa
    Shimo, Toshiro
    Mizutoh, Akiko
    Moriya, Takuya
    Sonoo, Hiroshi
    BREAST CANCER, 2015, 22 (03) : 292 - 299
  • [43] Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial
    Papakonstantinou, Antroula
    Matikas, Alexios
    Bengtsson, Nils Olof
    Malmstrom, Per
    Hedayati, Elham
    Steger, Guenther
    Untch, Michael
    Hubbert, Laila
    Johansson, Hemming
    Hellstrom, Mats
    Gnant, Michael
    Loibl, Sibylle
    Greil, Richard
    Moebus, Volker
    Foukakis, Theodoros
    Bergh, Jonas
    CANCER, 2020, 126 (06) : 1175 - 1182
  • [44] HER2-Positive Early Breast Cancer and Trastuzumab: A Surgeon’s Perspective
    Swati Kulkarni
    David G. Hicks
    Annals of Surgical Oncology, 2008, 15 : 1677 - 1688
  • [45] ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer
    Paplomata, Elisavet
    Nahta, Rita
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (03) : 335 - 341
  • [46] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [47] HER2-Positive early breast cancer and trastuzumab: A surgeon's perspective
    Kulkarni, Swati
    Hicks, David G.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (06) : 1677 - 1688
  • [48] A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer
    Dent, S.
    Ammendolea, C.
    Christofides, A.
    Edwards, S.
    Incekol, D.
    Pourmirza, B.
    Kfoury, S.
    Poirier, B.
    CURRENT ONCOLOGY, 2019, 26 (01) : E70 - E80
  • [49] The Effect of Adding Pertuzumab to Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer
    Al-Azawi, Ahmed
    Hneua, Riyadh Abd-Alrasool
    Hameed, Rana Majeed
    Hassan, Duha Maithem
    JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (03): : 197 - 200
  • [50] Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People's Republic of China
    Zhou, Ping
    Jiang, Yi-Zhou
    Hu, Xin
    Sun, Wei
    Liu, Yi-Rong
    Liu, Fang
    Luo, Rong-Cheng
    Shao, Zhi-Ming
    ONCOTARGETS AND THERAPY, 2016, 9 : 2287 - 2295
12345